<DOC>
	<DOCNO>NCT02803840</DOCNO>
	<brief_summary>Patients Diffuse Large B-cell Lymphoma indication palliative radiotherapy treat low-dose radiation ( 2 x 2 Gy ) symptomatic site . The primary endpoint study response rate Quality Life patient ( QoL ) .</brief_summary>
	<brief_title>Low-dose Radiotherapy Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Response plan 21-day completion treatment . Response assessment base standard definition World Health Organization use complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) , progressive disease ( PD ) response assessment criterion . The efficacy treatment consist reduction great 50 % maximum diameter radiate mass ( PR + CR ) . QoL evaluate use European Organization Research Treatment Cancer ( EORTC ) QLQ-C30 3.0 version questionnaire . The QLQ-C30 questionnaire self administer patient baseline 21 day treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Patients histologically proven diagnosis DLBCL indication palliative radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Large B-Cell</keyword>
	<keyword>Diffuse</keyword>
</DOC>